Adicet Bio Appoints Dr. Julie Maltzman as New Chief Medical Officer for Clinical Development

Adicet Bio Welcomes New Chief Medical Officer to Propel Clinical Development

Adicet Bio, Inc., a clinical-stage biotechnology company specializing in allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, announces the appointment of Dr. Julie Maltzman as its new Chief Medical Officer, effective January 13, 2025. Dr. Maltzman, who boasts over 20 years of experience in clinical development, particularly in oncology and autoimmune conditions, is poised to lead Adicet’s clinical development strategy. Her expertise will be instrumental in advancing the company’s promising pipeline, which includes the ADI-001 and ADI-270 programs.

The appointment comes at a crucial moment for Adicet, as the company experiences heightened momentum in its clinical trials. More sites are being activated, and patient enrollment is on the rise, a positive indicator for the innovative therapies in development. Chen Schor, President and CEO of Adicet Bio, expresses his enthusiasm for Dr. Maltzman joining the team, noting her proven track record in guiding multiple products from early research stages to successful global approvals. This experience will be vital as Adicet ramps up its efforts in clinical trial enrollments, aiming to bring its novel therapies to market.

Dr. Maltzman succeeds Dr. Francesco Galimi, who has completed his tenure at the company. Her previous roles include Chief Medical Officer at IconOVir Bio and Vice President, Global Head of GI Cancers and Cancer Immunotherapy at Roche/Genentech, where she played a key role in the global registration and commercialization of the combination therapy Tecentriq+Avastin®. In her statement, Dr. Maltzman emphasizes her excitement about joining Adicet at this pivotal time, highlighting the transformative potential of the company’s allogeneic gamma delta CAR T cell platform for patients facing severe oncologic and autoimmune challenges.

In addition to her new role, Dr. Maltzman’s background in developing therapies for refractory conditions positions her well to address the critical needs of patients. Adicet’s innovative approach aims to provide new curative treatment options, which could significantly impact the lives of those affected by these challenging diseases. The company’s leadership is optimistic that Dr. Maltzman’s appointment will catalyze progress in their clinical development initiatives, ultimately leading to advancements in patient care.

As Adicet Bio continues to navigate its clinical journey, the leadership transition brings renewed hope and strategic direction, reinforcing the company’s commitment to pioneering therapies that leverage the unique capabilities of gamma delta T cell technology.